DUBLIN–(BUSINESS WIRE)–The “Europe CAR-T Cell Therapy Market Size, Trends & Growth Opportunity, By Type, By Application, By End-user By country and Forecast till 2027.” report has been added to ResearchAndMarkets.com’s offering.
The Europe CAR-T Cell Therapy market was valued at USD 396.21 Mn in 2021 which expected to reach USD 1,904.40 Mn by 2027 at a CAGR 30.45% from 2020-2027.
Company Profiles
Mustang Bio Inc
Calgene Corporation
Bluebird Bio Inc.
Kite Pharma, Inc
CARsgen Therapeutics, Ltd.
Legend Biotech
Immune Therapeutics
Pfizer Inc
Bellicum Pharmaceuticals, Inc
Sorrento Therapeutics, Inc
Novartis
The CAR-T Cell Therapy market is a conceptual examination of all commercial activities related to CAR-T Cell Therapy, either directly or indirectly. As a result, a new investor can learn about CAR-T Cell Therapy firms, their important products, their basic strategy, key CAR-T Cell Therapy market trends, and more.
Market Drivers
Increasing approvals for CAR-T cell therapy products.
Increase in awareness about the new approach to treat cancer leads to increase in demand for the CAR-T cell therapy products. Thus, the key players in market are engaged in developing new products & thereby drive the growth of Europe CAR-T Cell Market.
For Instance, in June 2020, Kite Pharma, received approval to implement a variation to the Yescarta (axicabtagene ciloleucel) Marketing Authorization from the European Medicine Agency for end-to-end manufacturing. With this approval, Kite’s European manufacturing facility, designed & dedicated to the manufacture of individualized cell therapies, is now fully operational.
Market Restraints
CAR T therapies often come with unique drug development challenges. Some potential challenges associated with CAR T development is likely to hamper the growth of the Europe CAR-T Cell Therapy market. The potential challenges include limited guidance, manufacturing and distribution logistics, products safety etc.
Moreover, high cost involved in research & development for CAR-T cell therapies & lack of expertise as well as inadequate knowledge about CAR-T cell therapies are the major factors among others acting as restraints, and will further challenge the market in the forecast period.
Impact of COVID-19
Many businesses have seen their operations & financial performance suffer as a result of the COVID-19 pandemic and a slowing of global research activity. The negative impact is mostly due to the closure of academic & research institutes, as well as testing laboratories. As a result, the clinical trials conducted for the car T cell therapy has been delayed.
COVID-19 is posing a significant threat to health of vulnerable patients, like immunocompromised patients. CAR-T-cell therapy recipients are at high risk of poor COVID-19 due to their severely immunocompromised state, caused by prior lymphodepleting immunochemotherapy & CAR-T-cell therapy related side effects like B-cell depletion, hypogammaglobulinemia, and cytopenias.
Market Segmentation
By Type
Abecma
Breyanzi
Kymriah
Tecartus
Yescarta
By Application
Cancer
Lymphoma
Others
By End-user
Hospitals
Specialty Clinics
Others
By Country
Germany
France
UK
Turkey
Switzerland
Norway
Sweden
Spain
Denmark
Finland
Iceland
Poland
Luxembourg
Netherlands
Belgium
Key Questions Addressed by the Report
What are the Key Opportunities in Europe CAR-T Cell Therapy Market?
What will be the growth rate from 2021 to 2027?
Which segment/region will have highest growth?
What are the factors that will impact/drive the Market?
What is the competitive Landscape in the Industry?
What is the role of key players in the value chain?
For more information about this report visit https://www.researchandmarkets.com/r/s9x78g
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
